鼻一氧化氮作为慢性鼻窦炎黏膜健康长期监测与预后生物标志物
该研究纳入32例慢性鼻窦炎患者,在初次内镜鼻窦手术后5年随访中,发现鼻一氧化氮水平在术后1个月、6个月和5年较基线升高,且5年时与Lund-Kennedy内镜评分呈显著负相关。需再次手术的患者基线及术后6个月鼻一氧化氮水平显著低于未再手术者,提示鼻一氧化氮可作为无创长期监测和预后标志物。
要点
- 鼻一氧化氮在术后5年仍与内镜评分负相关,可长期监测疾病严重度。
- 需再次手术者基线及术后6个月鼻一氧化氮显著更低,有预后价值。
- 鼻一氧化氮或可无创辅助慢性鼻窦炎术后随访决策。
核心结论
- 鼻一氧化氮可能作为无创长期生物标志物,用于监测慢性鼻窦炎患者鼻窦疾病严重程度并预判再次手术风险。
研究设计与样本
- 前瞻性队列研究,纳入2013年1月至2015年1月在本机构接受初次内镜鼻窦手术的慢性鼻窦炎患者,在基线、术后1个月、6个月和5年测量鼻一氧化氮、Lund-Kennedy内镜评分和SNOT-22评分,共32例完成5年随访。
主要发现
- 术后1个月、6个月和5年的鼻一氧化氮水平均较基线升高。
- 术后5年鼻一氧化氮与Lund-Kennedy内镜评分呈显著负相关。
- 5年随访期间8例接受再次内镜鼻窦手术,其基线及术后6个月鼻一氧化氮水平显著低于未再手术者,尽管影像学严重程度相当。
关键数值与推荐
- 鼻一氧化氮与Lund-Kennedy内镜评分在术后5年呈显著负相关。
- 再次手术组基线及术后6个月鼻一氧化氮水平显著低于未再手术组。
临床怎么用
- 可将鼻一氧化氮作为慢性鼻窦炎术后长期无创监测工具,辅助评估黏膜炎症状态和再次手术风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nasal nitric oxide (nNO) is a potential biomarker of chronic rhinosinusitis (CRS), and correlates well with endoscopic and radiologic severity of disease. However, the long-term profile of nNO as a biomarker is not established in the literature. The objectives of our study were to examine whether nNO can maintain this correlation in a 5-year follow-up after endoscopic sinus surgery (ESS) and to investigate whether nNO value can be used to prognosticate revision rates in patients with CRS. METHODS: We enrolled CRS patients 5 years after initial ESS at our institution. Patients underwent initial ESS at our institution between January 2013 and January 2015. Patients prospectively had the following measurements at baseline, 1 month, 6 months, and 5 years post-ESS: nNO levels, Lund-Kennedy Endoscopy Score (LKES), and 22-item Sino-Nasal Outcome Test-22 (SNOT-22) score. We also compared the nNO levels between patients who underwent revision ESS and those who did not. RESULTS: There were 32 patients included in the study with 8 patients undergoing revision ESS during the 5-year follow-up. nNO levels were elevated at 1 month, 6 months, and 5 years post-ESS compared to baseline. A significant negative correlation between nNO and LKES was found at 5 years post-ESS. nNO levels were significantly reduced at baseline and 6 months post-ESS in the revision cohort compared to the nonrevision cohort despite having comparable radiologic severity. CONCLUSION: nNO may serve as a noninvasive long-term biomarker to monitor sinus disease severity and to prognosticate results in patients with CRS. This has implications for potential integration into clinical practice.
引用
- Lee DJ, Yip J, Lee JM, et al. Nasal nitric oxide as a long-term monitoring and prognostic biomarker of mucosal health in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2020. PMID: 32279461. doi:10.1002/alr.22581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。